Meningeal immunity and “Interstitial” therapy: a new paradigm for immunotherapy in glioblastoma - Takeaways - MDSpire

Meningeal immunity and “Interstitial” therapy: a new paradigm for immunotherapy in glioblastoma

  • By

  • Hongan Fei

  • Xichao Wen

  • Wensong Wu

  • HaiPeng Liu

  • Haipeng Xie

  • Yan Wang

  • Kebin Zheng

  • Zhaomu Zeng

  • Zetong Bai

  • June 15, 2026

  • 0 min

Share

  • 1

    Glioblastoma (GBM) is an aggressive brain tumor with a poor prognosis, highlighting the need for novel therapeutic strategies.

  • 2

    Traditional immunotherapy approaches have shown limited success in GBM due to barriers like the blood-brain barrier and an immunosuppressive tumor microenvironment.

  • 3

    Recent discoveries of meningeal lymphatic vessels and resident border-associated macrophages (rBAMs) provide new insights for enhancing GBM immunotherapy.

  • 4

    Meningeal vascular blockage can expand rBAMs and improve T cell responses against glioblastoma, suggesting a potential therapeutic target.

  • 5

    Interstitial immunotherapy aims to leverage the meningeal immune system to overcome immunosuppressive barriers and enhance anti-tumor immunity in GBM.

Original Source(s)

Meningeal immunity and “Interstitial” therapy: a new paradigm for immunotherapy in glioblastoma

  • by Hongan Fei, Xichao Wen, Wensong Wu, HaiPeng Liu, Haipeng Xie, Yan Wang, Kebin Zheng, Zhaomu Zeng, Zetong Bai

  • June 15, 2026

Related Content

Improving access to therapeutic clinical trials: a randomized controlled trial of GUIDE navigation and reimbursement

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer

Postoperative anastomotic leakage after colon cancer surgery may reduce long-term survival